# Negev Capital

> Negev Capital is a VC fund backing Biotechnology and Health Care. See 16 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Grand Cayman, Cayman Islands
- Total investments: 16
- Last investment: Apr 2025
- Lead investor: 38%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/negev-capital/
- X (Twitter): https://twitter.com/IBelotsky
- Website: https://negevcap.com

Negev Capital is a psychedelic medical intervention investment fund with assets of USD$21+ million. We invest in drug discovery, with a focus on preclinical and/or Phase 1 stages of development. We aim to support those early stage companies in need of capital that promote the thoughtful, responsible, and therapeutic use of psychedelicinterventions for neuropsychiatric disorders; as well as those who have excellent management and science teams, and robust IP. Negev believes that psychedelic medications will be not only disruptive to the practice of psychiatry but hold the potential to reduce enormous amounts of human suffering, and is committed to helping the field mature, and further promote ways for these treatments to reach all of those in need.

## Contacts

5 contacts available for Negev Capital. Shizune tracks 2 team members at Negev Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/negev-capital?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 10 | 63% |
| Health Care | 8 | 50% |
| Medical | 4 | 25% |
| Pharmaceutical | 4 | 25% |
| Therapeutics | 3 | 19% |

14 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 5 | 31% |
| Post-IPO Equity | 3 | 19% |
| Series A | 2 | 13% |
| Series B | 2 | 13% |
| Funding Round | 1 | 6% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 7 | 44% |
| Canada | 5 | 31% |
| United Kingdom | 1 | 6% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Ken Belotsky | Partner | 5 | https://shizune.co/investors/profile/ken-belotsky |
| Vadim E. Uzberg | Partner | 1 | https://shizune.co/investors/profile/vadim-e-uzberg |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Filament Health | Filament Health is a company that uses hard extraction and drug discovery technology to get natural psychedelics into the hands of everyone who needs them as fast as possible. Filament Health has a strong natural psychedelic intellectual property portfolio based on novel extraction and purification methods. | $639.3K | Post-IPO Equity | Apr 03, 2025 |  |
| Filament Health | Filament Health is a company that uses hard extraction and drug discovery technology to get natural psychedelics into the hands of everyone who needs them as fast as possible. Filament Health has a strong natural psychedelic intellectual property portfolio based on novel extraction and purification methods. | $1.7M | Post-IPO Equity | Jun 03, 2024 |  |
| Filament Health | Filament Health is a company that uses hard extraction and drug discovery technology to get natural psychedelics into the hands of everyone who needs them as fast as possible. Filament Health has a strong natural psychedelic intellectual property portfolio based on novel extraction and purification methods. | $1.8M | Post-IPO Equity | Jul 19, 2023 |  |
| Gilgamesh Pharmaceuticals | Gilgamesh Pharmaceuticals focuses on developing therapeutics that target neuropsychiatric and central nervous system conditions using small molecules derived from research on psychedelic compounds. The company designs and tests compounds that aim to modulate brain pathways involved in mental health disorders while reducing hallucinogenic effects.Its pipeline includes drug candidates intended for conditions such as depression, anxiety, and substance use disorders. Gilgamesh Pharmaceuticals conducts preclinical and clinical studies to evaluate the safety, dosing, and efficacy of its compounds. The company integrates medicinal chemistry, neuroscience, and clinical research to support drug development and regulatory progression. | $39M | Series B | Dec 15, 2022 |  |
| Betterlife Pharma | BetterLife Pharma Inc. is an emerging biotechnology company engaged in the development and commercialization of therapeutic pharmaceuticals as well as drug delivery platform technologies. BetterLife is refining and developing drug candidates from a broad set of complementary interferon-based technologies which have the potential to engage theimmune system to fight virus infections, such as the coronavirus disease (COVID-19) and human papillomavirus (HPV), and/or to directly inhibit tumours to treat specific types of cancer. | $474K | Post-IPO Equity | Dec 07, 2022 |  |
| Xylo Bio | Xylo Bio is a drug development company that focuses on next-generation psychedelics. With psychedelic molecules as the starting point, our goal is to develop medicines that are widely available as improved treatments to currently available SSRI medications. | $3.2M | Seed | Oct 27, 2022 |  |
| Filament Health | Filament Health is a company that uses hard extraction and drug discovery technology to get natural psychedelics into the hands of everyone who needs them as fast as possible. Filament Health has a strong natural psychedelic intellectual property portfolio based on novel extraction and purification methods. | $2.5M | Post-IPO Equity | Jun 30, 2022 |  |
| Reset Pharmaceuticals | Reset Pharma is a biotechnology company that focuses on the development and commercialization of novel psychedelic treatments for patients with life-threatening illnesses, including cancer. Its program focuses on psilocybin with psychotherapy for patients with cancer-related demoralization, anxiety, and depression. | $11.1M | Series A | Feb 16, 2022 |  |
| Mindstate Design Labs | Mindstate Design Labs is a clinical-stage AI neuroengineering platform developing novel psychoactive drug classes for psychiatric disease indications. The company's Osmanthus ensemble of AI models maps the molecular biology of human emotional and cognitive states by integrating the world’s largest datasets of psychoactive pharmacology andsubjective experience. Mindstate's lead program MSD-001 received FDA and EMA approval for Phase I human trials in 2024.Mindstate Design Labs is a Y Combinator company backed by Initialized Capital and other top-tier investors including the founders of OpenAI, Neuralink, Coinbase, Instacart, AngelList, Twitch, and IVADO. The company was founded by biotech venture investor & serial operator Dillan DiNardo and by computer scientist & evolutionary biologist Dr. Thomas Ray, who is famous for instantiating biological phenomena in emergent machine learning systems. | $11.5M | Seed | Feb 10, 2022 |  |
| Clairvoyant Therapeutics | Clairvoyant Therapeutics is a biotechnology company changing the face of psychedelic therapy with a speed-to-market clinical strategy. | $1.8M | Seed | Nov 30, 2021 |  |

10 of 16 investments shown.

## Co-investors
- [PsyMed Ventures](https://shizune.co/investors/profile/psychedelic-medicine-syndicate) — VC Fund, 4 deals together
- [Ambria Capital](https://shizune.co/investors/profile/ambria-capital) — VC Fund, 3 deals together
- [Empath Ventures](https://shizune.co/investors/profile/empath-ventures) — VC Fund, 3 deals together
- [Palo Santo Fund](https://shizune.co/investors/profile/palo-santo-venture-fund) — VC Fund, 3 deals together
- [Ayuh Ventures](https://shizune.co/investors/profile/ayuh-ventures) — VC Fund, 2 deals together
- [JLS Fund](https://shizune.co/investors/profile/jls-fund) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Artesian VC](https://shizune.co/investors/profile/artesian-capital-management) — VC Fund
- [Blackbird Ventures](https://shizune.co/investors/profile/blackbird-ventures-australia) — VC Fund

## Featured in investor lists
- [Biotech Investors in Australia](https://shizune.co/investors/biotech-investors-australia)
- [Biotech VC Funds in Australia](https://shizune.co/investors/biotech-vc-funds-australia)
- [Biotechnology Investors in Australia](https://shizune.co/investors/biotechnology-investors-australia)
- [Biotechnology VC Funds in Australia](https://shizune.co/investors/biotechnology-vc-funds-australia)
- [Biotech VC Funds in Oceania](https://shizune.co/investors/biotech-vc-funds-oceania)
- [Life Science Investors in Canada](https://shizune.co/investors/life-science-investors-canada)

## FAQ

### What does Negev Capital invest in?

Negev Capital invests primarily in Biotechnology, Health Care and Medical startups, most often at Seed and Post-IPO Equity stage. Most of the 16 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Negev Capital?

Public channels for Negev Capital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Negev Capital?

The team at Negev Capital includes Ken Belotsky (Partner) and Vadim E. Uzberg (Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co